Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.

Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.
复制标题

DOI:
10.1016/j.celrep.2013.01.023
复制
发表时间:
2013-02-21
期刊:
影响因子:
8.8
通讯作者:
Fingeroth JD
Fingeroth JD
中科院分区:
生物学1区
文献类型:
--
作者:
Ogembo JG;Kannan L;Ghiran I;Nicholson-Weller A;Finberg RW;Tsokos GC;Fingeroth JD

文献摘要

参考文献

被引文献

相似文献

Epstein-Barr 病毒 (EBV) 附着在原代 B 细胞上启动病毒进入。虽然 CD21 是 EBVgp350/220 唯一已知的受体,但最近的一份报告记录了 EBV 感染 CD21 遗传缺陷患者的 B 细胞。在正常静息 B 细胞上,CD21 形成两种膜复合物,一种与 CD19 形成,另一种与 CD35 形成。尽管 CD21/CD19 复合物广泛保留在永生化和 B 细胞肿瘤系中,但相关的补体调节蛋白 CD35 却丢失了。为了确定 CD35 在初始感染中的作用,我们用 CD35、CD21 或两者转导 CD21 阴性前 B 细胞和骨髓性白血病系。单独表达CD35的细胞结合gp350/220,并在共表达融合受体HLA II时被潜伏感染。 CD35 介导的感染的时间、生物物理和结构特征与 CD21 不同。 CD35 作为 EBV 受体的鉴定揭示了在原发感染中的显着作用,解决了尚未解决的病毒向性问题,并强调了 EBVgp350/220 对于疫苗开发的重要性。
Epstein-Barr virus (EBV) attachment to primary B-cells initiates virus entry. While CD21 is the only known receptor for EBVgp350/220 a recent report documents EBV infects B-cells from a patient genetically deficient in CD21. On normal resting B-cells CD21 forms two membrane complexes, one with CD19 another with CD35. Whereas the CD21/CD19 complex is widely retained on immortalized and B-cell tumor lines, the related complement-regulatory protein CD35 is lost. To determine the role(s) of CD35 in initial infection, we transduced a CD21-negative pre-B-cell and myeloid leukemia line with CD35, CD21 or both. Cells expressing CD35 alone bound gp350/220 and became latently infected when the fusion receptor HLA II was co-expressed. Temporal, biophysical and structural characteristics of CD35-mediated infection were distinct from CD21. Identification of CD35 as an EBV receptor uncovers a salient role in primary infection, addresses unsettled questions of virus tropism, and underscores the importance of EBVgp350/220 for vaccine development.
DOI: 10.1371/journal.pgen.1000287
发表时间: 2008-11
期刊: PLoS genetics
影响因子: 4.5
作者:
Choy E;Yelensky R;Bonakdar S;Plenge RM;Saxena R;De Jager PL;Shaw SY;Wolfish CS;Slavik JM;Cotsapas C;Rivas M;Dermitzakis ET;Cahir-McFarland E;Kieff E;Hafler D;Daly MJ;Altshuler D
通讯作者: Altshuler D
DOI: 10.4049/jimmunol.174.11.6599
发表时间: 2005-06-01
影响因子: 4.4
作者:
Gross, AJ;Hochberg, D;Thorley-Lawson, DA
通讯作者: Thorley-Lawson, DA
DOI: 10.1002/ijc.2910270209
发表时间: 1981-01-01
影响因子: 6.4
作者:
EINHORN, L;KLEIN, E
通讯作者: KLEIN, E
DOI: 10.1084/jem.168.5.1699
发表时间: 1988-11-01
期刊: The Journal of experimental medicine
影响因子: --
作者:
Klickstein LB;Bartow TJ;Miletic V;Rabson LD;Smith JA;Fearon DT
通讯作者: Fearon DT
DOI: 10.1182/blood-2010-05-285452
发表时间: 2010-11-25
期刊: BLOOD
影响因子: 20.3
作者:
Calattini, Sara;Sereti, Irini;Cohen, Jeffrey I.
通讯作者: Cohen, Jeffrey I.